Dolutegravir levels with TB prevention in children
Treatments studied
Part of Infections clinical trials.
This study tests how dolutegravir (an HIV medicine) works in children when taken with weekly rifapentine and isoniazid (medicines to prevent tuberculosis). It may help find the right dose for kids who have HIV and are at risk for TB.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be between 4 weeks and 12 years old.
- Your child must have HIV, either starting or continuing treatment.
- Your child must weigh at least 4 kilograms.
- Your child cannot have active tuberculosis, based on a doctor's evaluation and tests.
- Your child cannot be taking any medicines that interact badly with dolutegravir or the TB prevention medicines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at the right way to dose dolutegravir (an HIV medicine) in young children who also have active tuberculosis (TB). Doctors will measure how the medicine moves through the body, especially when standard vs higher-dose rifampicin is used.
This trial studies whether taking rifapentine every day is safe and helps prevent active tuberculosis (TB) in people who have latent TB infection. It aims to find the best way to stop TB from becoming a serious illness later.
This trial tests a shorter, safer treatment for people with latent TB infection (TB germs in your body but not making you sick). The goal is to prevent you from getting sick with active TB later.
This study tests a daily combination of two medicines, rifapentine and isoniazid, to prevent tuberculosis (TB) in children under 13 years old. It aims to see if this short treatment is safe and works well for kids, including those living with HIV.
This study checks how safe and well two HIV medicines work in children ages 6 to under 12. It also measures drug levels in the body to guide dosing and watch for side effects.
This trial tests a two-drug HIV treatment for people who are new to HIV therapy and also have tuberculosis. It compares the two-drug combination to the standard three-drug regimen, with the goal of making treatment simpler while still being effective.
Hear when a new Latent Tuberculosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.